RNAi-mediated knockdown of the CLN3 gene inhibits proliferation and promotes apoptosis in drug-resistant ovarian cancer cells

Mao,Dongwei; Che,Jianhua; Han,Shiyu; Zhao,Honghui; Zhu,Yumei; Zhu,Hong

doi:10.3892/mmr.2015.4238

RNAi-mediated knockdown of the CLN3 gene inhibits proliferation and promotes apoptosis in drug-resistant ovarian cancer cells

Authors:
- Dongwei Mao
- Jianhua Che
- Shiyu Han
- Honghui Zhao
- Yumei Zhu
- Hong Zhu
View Affiliations

Affiliations: Department of Gynaecology and Obstetrics, The Fourth Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang 150001, P.R. China, Department of Gynaecology, The Second Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang 150037, P.R. China
Published online on: August 21, 2015 https://doi.org/10.3892/mmr.2015.4238
Pages: 6635-6641
Copyright: © Mao et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

CLN3 is a recently identified anti-apoptotic gene, which has been demonstrated to be highly expressed in a diverse range of cancer cell lines, including ovarian cancer. In the present study, RNA interference, mediated by a lentivirus expressing CLN3 short hairpin RNA (shRNA) was utilized to knockdown the expression of CLN3 in the A2780 human ovarian cancer cell line, and its cisplatin‑resistant and carboplatin‑resistant sublines, A2780/DDP and A2780/CBP cells. It was revealed that the mRNA and protein expression levels of CLN3 were significantly reduced in the CLN3‑specific shRNA‑transduced cells, compared with the untransduced and control shRNA‑transduced cells. In addition, specific knockdown of CLN3 in these cells inhibited cell proliferation and led to cell cycle arrest at the G0/G1 phase, with eventual apoptosis. CLN3 knockdown caused increases in the levels of Bax, FAX, cleaved‑caspase 3, cleaved‑caspase 8 and cleaved‑RARP, but decreased the level of Bcl‑2. Finally, it was observed that CLN3 depletion markedly reduced the half maximum inhibitory concentration in the A2780/DDP and A2780/CBP cells. Taken together, these data suggested that CLN3 is involved in tumorigenesis and drug resistance in ovarian cancer, and may serve as a promising therapeutic target for its treatment.

View Figures

View References

1	Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
2	Heintz AP, Odicino F, Maisonneuve P, Beller U, Benedet JL, Creasman WT, Ngan HY and Pecorelli S: Carcinoma of the ovary. Int J Gynaecol Obstet. 83(Suppl 1): 135–166. 2003. View Article : Google Scholar
3	Jelovac D and Armstrong DK: Recent progress in the diagnosis and treatment of ovarian cancer. CA Cancer J Clin. 61:183–203. 2011. View Article : Google Scholar : PubMed/NCBI
4	Isolation of a novel gene underlying Batten disease, CLN3. The International Batten Disease Consortium. Cell. 82:949–957. 1995. View Article : Google Scholar : PubMed/NCBI
5	Rakheja D, Narayan SB, Pastor JV and Bennett MJ: CLN3P, the Batten disease protein, localizes to membrane lipid rafts (detergent-resistant membranes). Biochem Biophys Res Commun. 317:988–991. 2004. View Article : Google Scholar : PubMed/NCBI
6	Phillips SN, Benedict JW, Weimer JM and Pearce DA: CLN3, the protein associated with batten disease: Structure, function and localization. J Neurosci Res. 79:573–583. 2005. View Article : Google Scholar : PubMed/NCBI
7	Metcalf DJ, Calvi AA, Seaman M, Mitchison HM and Cutler DF: Loss of the Batten disease gene CLN3 prevents exit from the TGN of the mannose 6-phosphate receptor. Traffic. 9:1905–1914. 2008. View Article : Google Scholar : PubMed/NCBI
8	Cortese A, Tucci A, Piccolo G, Galimberti CA, Fratta P, Marchioni E, Grampa G, Cereda C, Grieco G, Ricca I, et al: Novel CLN3 mutation causing autophagic vacuolar myopathy. Neurology. 82:2072–2076. 2014. View Article : Google Scholar : PubMed/NCBI
9	Puranam KL, Guo WX, Qian WH, Nikbakht K and Boustany RM: CLN3 defines a novel antiapoptotic pathway operative in neurodegeneration and mediated by ceramide. Mol Genet Metab. 66:294–308. 1999. View Article : Google Scholar : PubMed/NCBI
10	Narayan SB, Rakheja D, Pastor JV, Rosenblatt K, Greene SR, Yang J, Wolf BA and Bennett MJ: Over-expression of CLN3P, the Batten disease protein, inhibits PANDER-induced apoptosis in neuroblastoma cells: Further evidence that CLN3P has anti-apoptotic properties. Mol Genet Metab. 88:178–183. 2006. View Article : Google Scholar : PubMed/NCBI
11	Rylova SN, Amalfitano A, Persaud-Sawin DA, Guo WX, Chang J, Jansen PJ, Proia AD and Boustany RM: The CLN3 gene is a novel molecular target for cancer drug discovery. Cancer Res. 62:801–808. 2002.PubMed/NCBI
12	Zhu X, Huang Z, Chen Y, Zhou J, Hu S, Zhi Q, Song S, Wang Y, Wan D, Gu W, et al: Effect of CLN3 silencing by RNA interference on the proliferation and apoptosis of human colorectal cancer cells. Biomed Pharmacother. 68:253–258. 2014. View Article : Google Scholar : PubMed/NCBI
13	Wu D, Liu J, Wu B, Tu B, Zhu W and Luo J: The Batten disease gene CLN3 confers resistance to endoplasmic reticulum stress induced by tunicamycin. Biochem Biophys Res Commun. 447:115–120. 2014. View Article : Google Scholar : PubMed/NCBI
14	Dean M, Rzhetsky A and Allikmets R: The human ATP-binding cassette (ABC) transporter superfamily. Genome Res. 11:1156–1166. 2001. View Article : Google Scholar : PubMed/NCBI
15	Izquierdo MA, Neefjes JJ, Mathari AE, Flens MJ, Scheffer GL and Scheper RJ: Overexpression of the ABC transporter TAP in multidrug-resistant human cancer cell lines. Br J Cancer. 74:1961–1967. 1996. View Article : Google Scholar : PubMed/NCBI
16	Nooter K and Stoter G: Molecular mechanisms of multidrug resistance in cancer chemotherapy. Pathol Res Pract. 192:768–780. 1996. View Article : Google Scholar : PubMed/NCBI
17	Breier A, Gibalova L, Seres M, Barancik M and Sulova Z: New insight into p-glycoprotein as a drug target. Anticancer Agents Med Chem. 13:159–170. 2013. View Article : Google Scholar
18	Baguley BC: Multiple drug resistance mechanisms in cancer. Mol Biotechnol. 46:308–316. 2010. View Article : Google Scholar : PubMed/NCBI
19	Ambudkar SV, Kimchi-Sarfaty C, Sauna ZE and Gottesman MM: P-glycoprotein: From genomics to mechanism. Oncogene. 22:7468–7485. 2003. View Article : Google Scholar : PubMed/NCBI
20	Sauna ZE, Kim IW and Ambudkar SV: Genomics and the mechanism of P-glycoprotein (ABCB1). J Bioenerg Biomembr. 39:481–487. 2007. View Article : Google Scholar : PubMed/NCBI
21	Glavinas H, Krajcsi P, Cserepes J and Sarkadi B: The role of ABC transporters in drug resistance, metabolism and toxicity. Curr Drug Deliv. 1:27–42. 2004. View Article : Google Scholar
22	Tecedor L, Stein CS, Schultz ML, Farwanah H, Sandhoff K and Davidson BL: CLN3 loss disturbs membrane microdomain properties and protein transport in brain endothelial cells. J Neurosci. 33:18065–18079. 2013. View Article : Google Scholar : PubMed/NCBI